Art. -Nr.: HY-P10745A

Petrelintide acetate

(Synonyms: ZP8396 acetate)

Kundenbewertung

Based on 1 Customer Validation

Perelintide (ZP8396) acetate is a dual amylin and calcitonin receptor agonist (DACRA). Perelintide acetate elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Perelintide acetate can be utilized in diabetes research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.78%
Formel: C₁₈₅H₃₀₅N₄₉O₆₁.xC₂H₄O₂
Molecular Weight:4191.69 (free base)

Speicherung:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Petrelintide acetate Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- Parmacokinetics
- In Vivo
- Clinical Trial
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

hAMY3R

2.997 nM (EC₅₀)

hCTR

9.215 nM (EC₅₀)

In Vitro

Petrelintide acetate demonstrates agonistic activity against hAMY3R and hCTR in HEK-293 cells, with EC₅₀ of 2.997 and 9.215 nM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	T_1/2	T_max	C_max	AUC_0-t	AUC_0-∞
Rat^[1]	1 mg/kg	s.c.	26.2 h	24 h	4850 ng/mL	254046 ng·h/mL	286517 ng·h/mL

In Vivo

Petrelintide (0.04 mg/kg, s.c., every third day for a total of 10 doses) acetate reduces body weight and food intake in DIO rats^[1].
Petrelintide (2 nmol/kg, s.c., every second day for 30 days, or 10 nmol/kg, s.c., every fourth day for 30 days) acetate reduces food intake and body weight in DIO rats primarily by lowering intake of high fat diet^[2].
Petrelintide (2 nmol/kg, s.c., every second day for 30 days, or 10 nmol/kg, s.c., every fourth day for 30 days) acetate shows preferential fat mass loss and preservation of relative lean mass during weight loss in DIO rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

DIO rats^[1]
Dosage:

0.04 mg/kg
Administration:

s.c., every third day for a total of 10 doses
Result:

Significantly reduced body weight and food intake compared to the vehicle group.

Animal Model:

DIO rats^[2]
Dosage:

2, 10 nmol/kg
Administration:

s.c., every second day (2 nmol/kg) or every fourth day (10 nmol/kg) for 30 days
Result:

Resulted in significant lower relative body weight compared to vehicle.
Resulted in significant reduction of total cumulative intake of high fat diet compared to vehicle.
Exhibited no change in total cumulative intake of chow compared to vehicle.

Animal Model:

DIO rats^[3]
Dosage:

2, 10 nmol/kg
Administration:

s.c., every second day (2 nmol/kg) or every fourth day (10 nmol/kg) for 30 days
Result:

Resulted in significantly lower relative body weight compared to vehicle.
Resulted in significant reduction of fat mass in comparison to vehicle.
Resulted in significant preservation of relative lean mass in comparison to vehicle.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

Appearance Solid
Molecular Weight 4191.69 (free base)
Formel C₁₈₅H₃₀₅N₄₉O₆₁.xC₂H₄O₂
Color White to off-white
Synonyms

ZP8396 acetate
Sequence

{γGlu-arachidate}-Arg-Asp-Gly-Thr-Ala-Thr-Lys-Ala-Thr-Glu-Arg-Leu-Ala-{homoGlu}-Phe-Leu-Gln-Arg-Ser-Ser-Phe-{Sar}-Ala{NMeIle}-Leu-Ser-Ser-Thr-Glu-Val-Gly-Ser-Asn-Thr-{Hyp}-NH2 (Lactm bridge:Asp3-Lys8)
Sequence Shortening

{γGlu-arachidate}-RDGTATKATERLA-{homoGlu}-FLQRSSF-{Sar}-A{NMeIle}-LSSTEVGSNT-{Hyp}-NH2 (Lactm bridge:Asp3-Lys8)
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL; Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL; Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (296 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zong L, et al. Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment. J Med Chem. 2025 Jul 24;68(14):14907-14918. [Content Brief]

[2]. BILL V, et al. 1661-P: Petrelintide (ZP8396) Selectively Reduces Intake of High-Fat Diet in DIO Rats. Diabetes 14 June 2024; 73 (Supplement_1): 1661-P.

[3]. BILL V, et al. 1662-P: Petrelintide (ZP8396) Significantly Reduces Fat Mass while Preserving Lean Mass in DIO Rats. Diabetes 14 June 2024; 73 (Supplement_1): 1662-P.

[4]. JON G, et al. 1668-P: Novel Once-Weekly Amylin Analog Petrelintide (ZP8396) Is Well Tolerated with Improved GI Tolerability after Multiple Dosing, Diabetes, 2024;73(Supplement_1):1668-P

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Petrelintide acetate

Peptide Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Petrelintide acetate

Peptide Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Petrelintide acetate Related Classifications

HY-P10745A Related Classifications